Venatorx Pharmaceuticals’ second development-stage product in clinical development is VNRX-7145, an orally bioavailable beta-lactamase inhibitor (BLI) that in a fixed combination with the third generation orally bioavailable cephalosporin, ceftibuten, has the potential to rescue activity of the partner antibiotic against extended spectrum beta-lactamases (ESBLs) and key carbapenem-resistant Enterobacteriaceae, including those expressing Klebsiella pneumoniae carbapenemase (KPC) and Oxacillinase (OXA) carbapenemases.
Venatorx initiated enrollment in its Phase 1 clinical trial (ClinicalTrials.gov – NCT04243863) entitled, “A Randomized, Double Blind, Placebo-Controlled, Sequential Group, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single and Repeat Doses of VNRX-7145 in Healthy Adult Volunteers” in January 2020. In the first part of this first-in-human dose-ranging study, subjects will receive a single dose of VNRX-7145; in part 2, subjects will receive multiple doses of VNRX-7145 for 10 days.
This project has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201600029C.